Low Tumor PD-L1 Expression Identifies Responders to Neoadjuvant Leukocyte Interleukin Injection in Locally Advanced HNSCC | OncLive

Low PD-L1 expression and node-negative status identified oral cancer patients most likely to benefit from neoadjuvant leukocyte interleukin injection.

onclive.com

Signatera Is Submitted to Japan's PMDA for Companion Diagnostic Approval in MIBC | OncLive

Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.

onclive.com

Docirbrutinib Yields High Response Rates in MCL and CLL | OncLive

Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.

onclive.com

Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC | OncLive

Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.

onclive.com

Camrelizumab Plus Nab-Paclitaxel Yields Efficacy in Previously Treated Advanced Urothelial Carcinoma | OncLive

Later-line camrelizumab plus nab-paclitaxel produced durable responses in platinum-treated advanced urothelial carcinoma.

onclive.com

FDA Approves Rituximab Biosimilar for Hematologic Malignancies | OncLive

A rituximab biosimilar has been approved by the FDA.

onclive.com

Dr Cohen on FcRH5 as a Therapeutic Target in Multiple Myeloma | OncLive

Adam D. Cohen, MD, discusses the potential role of FcRH5 as a target and the ongoing investigation of cevostamab in multiple myeloma.

onclive.com

Mayo Clinic–Led Study Finds No Improvement in Overall Survival From Longer Multiple Myeloma Maintenance Therapy | OncLive

Continuing maintenance therapy with lenalidomide beyond 2 years after initial treatment did not improve overall survival in standard-risk myeloma.

onclive.com

FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan for Neuroendocrine Carcinomas | OncLive

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.

onclive.com

Tislelizumab Plus Gemcitabine Shows Efficacy in Cisplatin-Ineligible Urothelial Carcinoma | OncLive

First-line tislelizumab plus gemcitabine produced durable responses in platinum-ineligible locally advanced or metastatic urothelial carcinoma.

onclive.com

FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer | OncLive

Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.

onclive.com

NCCN Guidelines Add Gedatolisib-Based Regimens for Pretreated PIK3CA Wild-Type Advanced Breast Cancer | OncLive

Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN Guidelines for select patients with previously treated breast cancer.

onclive.com

Darlifarnib Plus Cabozantinib Yields ORRs Up to 50% in Cabozantinib-Naive ccRCC | OncLive

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

onclive.com

Frontline Zanubrutinib Plus Obinutuzumab Elicits Complete Responses in Older Patients With MCL | OncLive

Obinutuzumab plus zanubrutinib produced high complete response rates with manageable toxicity in older patients with previously untreated mantle cell lymphoma.

onclive.com

Rethinking Lung Cancer Screening Paradigms | OncLive

A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.

onclive.com

Dr Ferrarotto on the Investigation of Emi-Le in Aggressive Adenoid Cystic Carcinoma | OncLive

Renata Ferrarotto, MD, discusses the biologic rationale for and interim findings from a phase 1 study of Emi-Le in patients with aggressive ACC.

onclive.com

Dr Hurvitz on Evorpacept Plus Zanidatamab in Pretreated HER2+ Metastatic Breast Cancer | OncLive

Sara A. Hurvitz, MD, FACP, discusses the mechanism of action of evorpacept and data with the agent in pretreated HER2-positive metastatic breast cancer.

onclive.com

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS | OncLive

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

onclive.com

Baseline and On-Treatment QOL Improvements Track With Survival Benefits With Belzutifan or Everolimus in ccRCC | OncLive

A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.

onclive.com

Experimental Immunotherapy May Help Patients With High-Risk Bladder Cancer Avoid Bladder Removal Surgery | OncLive

A Mayo Clinic study found that a new immunotherapy helped patients with aggressive bladder cancer keep their bladder instead of having it removed.

onclive.com

Sarcoma Experts Answer FAQs About the Diagnosis and Multidisciplinary Management of Sarcoma | OncLive

Sarcoma management demands coordinated, subtype-specific care and treatment sensitivities delivered by a dedicated multidisciplinary team.

onclive.com

FDA sNDA Submission Is Planned for Selinexor Plus Ruxolitinib in Myelofibrosis | OncLive

A supplemental new drug application for selinexor plus ruxolitinib for myelofibrosis in August 2026 under the accelerated approval pathway.

onclive.com